Switch to:
More From Other Websites
Equity markets surge...so many stories – where to begin? Dec 17 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pozen, Inc. -... Dec 17 2014
POZEN Inc. Update on 2nd CRL from the FDA for YOSPRALA Call scheduled for 8:30 am ET today Dec 17 2014
POZEN INC /NC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 17 2014
POZEN’s YOSPRALA™ Receives Complete Response Letter from The FDA Dec 17 2014
POZEN’s YOSPRALA™ Receives Complete Response Letter from The FDA Dec 17 2014
6:30 am POZEN announced that its investigational drug candidates YOSPRALA 81/40 and 325/40 have... Dec 17 2014
OPEC's stubborn oil stance Dec 15 2014
POZN: Pozen Seeking New Partner For Yosprala Dec 01 2014
POZEN Inc. and Sanofi US Mutually Agree to Terminate U.S. Partnership for PA8140/PA32540 Call... Dec 01 2014
POZEN Inc. and Sanofi US Mutually Agree to Terminate U.S. Partnership for PA8140/PA32540 Dec 01 2014
POZEN INC /NC Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial... Dec 01 2014
POZEN Inc. and Sanofi US Mutually Agree to Terminate U.S. Partnership for PA8140/PA32540 Dec 01 2014
Geopolitical risk premium gone from oil: Pro Nov 18 2014
POZEN INC /NC Financials Nov 15 2014
McDonald's not out of woods: Strategist Nov 10 2014
10-Q for POZEN, Inc. Nov 08 2014
FDA Decision Nearing For Pozen Nov 06 2014
POZEN Inc. Earnings Call scheduled for 11:00 am ET today Nov 06 2014
Pozen posts 3Q profit Nov 06 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK